ily excretable metabolite with 5-to 10-fold higher solubility hyperuricemia in the USA has been allopurinol with vigorous than uric acid -offers a potentially useful alternative for the hydration, urinary alkalinization and osmotic diuresis. Urate prophylaxis and treatment of hyperuricemia.
allergy, glucose-6-phosphate dehydrogenase deficiency and malignant diseases and their treatment, has been associated pregnancy are listed as contraindications in the Uricozyme with high morbidity rates and delays in the delivery of chemopackage insert), six because they received the new recombitherapy, especially in patients with B cell or T cell acute lymnant urate oxidase (which recently became available for cliniphoblastic leukemia (ALL) and advanced-stage B cell noncal testing in a multicenter clinial trial), and four because they Hodgkin lymphoma (NHL).
1-6 The standard prophylaxis or did not receive methotrexate or 6-mercaptopurine as preintreatment of hyperuricemia in patients with neoplastic disduction therapy. Children with newly diagnosed non-B cell orders consists of allopurinol, vigorous hydration, urinary alk-ALL who were consecutively treated with allopurinol between alinization and osmotic diuresis. [2] [3] [4] [5] 7 By inhibiting the enzyme December 1991 and February 1994 served as historical conxanthine oxidase, hence uric acid formation, allopurinol thertrols. Informed consent was obtained from the parents or legal apy reduces the renal load of uric acid but increases the renal guardians of all patients. excretion of the uric acid precursors hypoxanthine and xanthine. 8 Unlike hypoxanthine, xanthine is actually less soluble than uric acid in urine. 9 In fact, occasional case reports of Chemotherapy xanthine nephropathy and calculi suggest that allopurinol treatment is detrimental to some patients. [10] [11] [12] [13] Patients with non-B cell ALL receiving non-recombinant urate Urate oxidase, by converting uric acid to allantoin -a readoxidase and historical controls were the subjects of two consecutive Total Therapy studies (XIIIA and XIIIB). with the first dose of urate oxidase treatment and did not receive subsequent doses, were excluded from the analysis. remission induction). Ninety-seven patients treated with urate oxidase were enrolled in the second study, XIIIB, which stratiAll comparisons were controlled at a type I error rate of ␣ = 0.05. All analyses were conducted using SAS Release fied and randomized patients to receive up-front 6-mercaptopurine (1 g/m 2 intravenously over 6 h) alone, or high-dose 6.11. methotrexate or fractionated lower-dose methotrexate (at the same dosages as those used in the preceding trial), followed at 24 h by a 6-mercaptopurine infusion. Approximatley 96 h Results and 72 h after the start of methotrexate and 6-mercaptopurine treatment, respectively, chemotherapy with prednisone,
The groups of patients given urate oxidase or allopurinol had similar presenting ages (median, 5.6 vs 5.7 years), leukocyte vincristine and daunorubicin was begun. Hence, during the first 96 h of treatment, patients in study XIIIB received more counts (11.7 vs 13. (data not shown). The decrease in uric acid levels was not only more pronounced but also more rapid in the urate oxidase group than in the allopurinol group (Figure 1 ). In the urate oxidase group, the proportions of patients with uric acid Supportive care levels below 1 mg/dl after 1 day and 2 days of treatment were 50.9 and 46.8%, respectively, compared with 1% and 1.8% All patients received hydration fluid with NaHCO 3 to maintain the urine pH у6.5 (to prevent methotrexate-induced in the allopurinol group (P Ͻ 0.001 for both comparisons). Moreover, the minimal uric acid levels among patients in the toxicities). Non-recombinant urate oxidase, diluted in 50 ml normal saline, was administered at 100 units/kg per day intraurate oxidase group were significantly lower than corresponding values in the allopurinol group: median (range), 0.6 (0-venously over 30 min for 5 days, under the auspices of US FDA IND 43183 and 46051. Allopurinol was given at 4.1) vs 2.3 (0.6-6.3) mg/dl, P Ͻ 0.001. Patients given urate oxidase also had better renal function, as indicated by lower 300 mg/m 2 per day orally for 5-13 days to historical controls. Oral phosphorous binder (aluminum hydroxide or calcium maximal levels of BUN (median, 11 vs 24 mg/dl, P Ͻ 0.001) or creatinine (median, 0.6 vs 0.7 mg/dl, P = 0.01). carbonate) was given to individual patients as indicated.
Although patients with B cell ALL or advanced-stage B cell NHL lacked historical controls, their responses to urate oxidase were nonetheless impressive. Plasma uric acid levels Determination of uric acid levels decreased during antineoplastic chemotherapy in each of the five patients with B cell ALL and in the three with stage III Plasma collected in an EDTA tube was used to measure uric acid levels. To block enzymatic degradation of uric acid by NHL (Figure 2 ), dropping below 1 mg/dl after 4 days of treatment. Renal function worsened transiently in a single case, in urate oxidase ex vivo, we maintained temperatures at 0°to 4°C during sampling, transport to the laboratory, and prepwhich the creatinine level increased from 1.4 mg/dl to 2.1 mg/dl on day 3, returning to normal (0.7 mg/dl) on day 6. aration for assay. The samples were assayed with the EKTA-CHEM 700 analyzer (Johnson & Johnson Clinical Diagnostics, None of the patients required dialysis for renal failure; however, six (4.5%) of the 134 children with ALL or B cell NHL Rochester, NY, USA), based on the oxidation of uric acid in the presence of exogenous urate oxidase (from Candida utilis) who received urate oxidase developed allergic reactions. All reactions (five grade 3 and one grade 2 according to the Comto form allantoin and hydrogen peroxide. Hydrogen peroxide then reacts with a leuco dye in the presence of peroxidase to mon Toxicity Criteria of the National Cancer Institute) occurred during infusion of the first dose of urate oxidase with produce a colored compound that is measured by reflectance spectophotometry. The lower limit of sensitivity was a median onset of 6 min (range 1-17 min). They were manifested as bronchospasm and hypoxemia in five patients, urti-0.5 mg/dl. caria in four, facial or lip swelling in two and hypotension or emesis in one each. All reactions resolved within 1-12 h (median 1 h) after treatment with intravenous diphenhydramStatistical analysis ine and a glucocorticoid, subcutaneous epinephrine and oxygen. Two-tailed Wilcoxon rank-sum tests were used to compare distributions of blood levels of uric acid, blood urea nitrogen One additional patient, a 12-year-old black boy with T cell ALL and a presenting leukocyte count of 410 × 10 9 /l had an (BUN), creatinine, calcium, phosphorous, and lactic dehydrogenase during the first 96 h of treatment, as well as presenting oxygen saturation of 90% without clinical symptoms during routine monitoring, 2 h after administration of the first dose of leukocyte counts, between the 119 patients with ALL who had received a full course of urate oxidase and the 129 controls urate oxidase. Methemoglobinemia (11.4%) was found at that time and peaked at 15.6% at 14 h. The child recovered comwho received allopurinol. The distribution of leukemic cell pletely without treatment 4 days later and was subsequently diagnosed to have glucose-6-phosphate dehydrogenase deficiency. Urate oxidase was not repeated in this child or the other six patients with allergic reactions.
Discussion
In this study, non-recombinant urate oxidase was more effective than allopurinol in the prevention and treatment of hyperuricemia, as in the small series reported by Masera et al.
17
Uric acid levels decreased to 4.1 mg/dl or lower (median, 0.6 mg/dl) in all of our patients with ALL or NHL during treatment with urate oxidase, despite the concomitant administration of cytoreductive chemotherapy. The results we report probably underestimate the clinical potential of the urate oxidase, since patients with non-B cell ALL were studied during treatment that is much less intensive than standard remission induction regimens for this disease. 24 Importantly, the more rapid uricolytic effects of urate oxidase compared to allopurinol (Figure 1 ) would be expected to shorten or eliminate
Figure 1
Comparison of plasma uric acid levels at diagnosis and during the first 2 days of up-front window therapy in patients receiving delays in chemotherapy due to hyperuricemia, a major con- lysis. 5, 25 In theory, the use of urate oxidase should facilitate the excretion of phosphorous, as it would obviate the need to alkalinize the urine, and phosphorus is more soluble in acidic urine. This prediction could not be tested in the present study because of the small number of patients at high risk of massive tumor cell lysis (eg those with B cell ALL or advanced-stage B cell NHL). Nonetheless, we would emphasize that none of our B cell ALL or stage III or IV Burkitt NHL cases treated with urate oxidase had renal failure requiring dialysis. By contrast, acute renal failure prompted hemodialysis in 10 of 40 patients with B cell ALL or advanced-stage NHL treated previously at this center 26 and 28 of 133 treated recently in the Pediatric Oncology Group (six of whom died of complications). 27 We attributed this difference to our recent use of urate oxidase and the adoption of 'reduction phase' therapy as pioneered by French investigators, which is associated with a lesser degree of tumor cell lysis than conventional therapy. 23 The frequency of allergic reactions complicating the use of non-recombinant urate oxidase has been uncertain. Masera et al 17 did not observe any adverse effects in their study of 30 patients, in contrast to the 4.5% incidence of allergic reactions, primarily bronchospasm and hypoxemia, noted here.
Figure 2
Plasma uric acid levels in patients with B cell ALL or
Whether this observation reflects inherent differences in the NHL, determined before and after treatment with chemotherapy and allergic status of our patients and those studied by Masera et 
